Read More

Incyte Corporation Announces Late Wednesday Phase 3 Data Showing Improvements In Facial And Total Body Repigmentation With Ruxolitinib Cream In Vitiligo Published In New England Journal Of Medicine

Data served as basis for recent FDA approval of ruxolitinib cream (Opzelura™) 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older Fifty-two

INCY

Read More

European Medicines Agency Committee For Medicinal Products For Human Use Adopts Opinion Recommending Authorization Of Moderna’s Omicron BA.4-BA.5 Targeting Bivalent Covid-19 Vaccine In The European Union

Positive recommendation follows the recent approval of Spikevax bivalent Original/Omicron BA.1 (mRNA-1273.214), a bivalent booster vaccine targeting the Omicron BA.1 subvariant, in September CAMBRIDGE, MA / ACCESSWIRE /

MRNA